Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
Background: Health technology assessment (HTA) has increased in importance in supporting payer decision making by assessing the relative effectiveness and cost effectiveness of new medicines. Thus, pharmaceutical companies need to address the HTA requirements early during development to improve reim...
Saved in:
Main Authors: | Ting Wang (Author), Neil McAuslane (Author), Lawrence Liberti (Author), Helga Gardarsdottir (Author), Wim Goettsch (Author), Hubert Leufkens (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
by: Ting Wang, et al.
Published: (2022) -
An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017-2018 using the OpERA methodology
by: Lawrence Liberti, et al.
Published: (2020) -
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
by: Hedi Schelleman, et al.
Published: (2015) -
Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
by: DiBonaventura MD, et al.
Published: (2013) -
Family Firms and Closed Companies in Germany and Spain
Published: (2023)